Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2024-10-29 Regulatory Filings
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 29, 2024, by Shuttle Pharmaceuticals Holdings, Inc. It reports a Regulation FD Disclosure about dosing patients in a Phase 2 clinical trial and includes a press release as Exhibit 99.1. The document is a current report on a material event, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather a disclosure of a significant corporate event. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2024-10-29 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. dated October 28, 2024. It reports a Regulation FD Disclosure about finalizing agreements for a Phase 2 clinical trial site enrollment. The document includes a press release as an exhibit and contains forward-looking statements. There are no financial statements or detailed financial data included. The Form 8-K is a current report used to announce significant events or disclosures outside of regular periodic filings. This is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. It is a regulatory filing reporting a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-10-28 English
Investor Presentation 2024
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. dated October 28, 2024. It announces a CEO presentation at the ThinkEquity Conference and the update of the corporate investor presentation. The document includes a press release and an investor presentation as exhibits. There are no financial statements or detailed financial data included, only announcements about the presentation and press release. The document is about disclosure of an investor presentation and related press release, not the presentation or financial report itself. Therefore, it fits the category of Investor Presentation (IP). The length is 7501 characters, which is sufficient for a detailed announcement and presentation text. The document is not a full annual or quarterly report, nor an earnings release or regulatory filing. Hence, the best classification is Investor Presentation (IP) with high confidence.
2024-10-28 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from Shuttle Pharmaceuticals Holdings, Inc. to the SEC requesting acceleration of the effective date of a registration statement on Form S-1. It is a formal communication related to a securities registration process, specifically an acceleration request under Rule 461 of the Securities Act. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory filing related to the registration process rather than a financial report or announcement of results. The document length is short (1454 characters), and it is a formal request letter, not a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2024-10-25 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a letter from a lead placement agent to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. This is related to capital raising activities and the registration of securities. The document is short (976 characters) and is a formal communication about a financing process, not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it pertains to the registration and timing of a securities offering.
2024-10-25 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 21, 2024, by Shuttle Pharmaceuticals Holdings, Inc. It details the closing of a financing offering involving senior secured convertible notes and warrants, including the amounts raised and terms of the offering. The document references previous filings and includes exhibits related to the securities purchase agreement and related instruments. The content focuses on a material definitive agreement and unregistered sales of equity securities, which are typical disclosures in a capital raising or financing update. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The primary subject is the update on the company's financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-10-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.